Last reviewed · How we verify
NCT06074874: IBA_ECP
Intestinal Biomarker Analysis After ECP for ICI Colitis
trial testing Intestinal tissue analysis in Colitis in 20 participants. Completed in 30 March 2024.
30 March 2024
Quick facts
| Lead sponsor | University of Freiburg |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 1 July 2023 |
| Primary completion | 30 March 2024 |
| Estimated completion | 30 March 2024 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Intestinal tissue analysis
Conditions studied
- Colitis — all drugs for Colitis →
- Immune Checkpoint Inhibitor-Related Colitis — all drugs for Immune Checkpoint Inhibitor-Related Colitis →
Sponsor
University of Freiburg
Who can join
18 and older, any sex, with Colitis or Immune Checkpoint Inhibitor-Related Colitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It was previously shown that ICI-colitis can be treated with extracorporeal photophoresis. Therefore this retrospective analysis is launched to study the chnages of immune cells in the peripheral blood and intestinal tract in an ICI colitis patient cohort. The analysis will include the evaluation of intestinal and peripheral blood biomarkers in patients with ICI colitis receiving ECP as a treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06074874
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colitis
Currently open trials in the same condition.
- NCT07196410 — KAN-004 for Immune-Related Diarrhea or Colitis · Phase 1 · recruiting
- NCT07047339 — Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis · Phase 2, PHASE3 · recruiting
- NCT06206707 — FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis · NA · recruiting
- NCT03819296 — Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer · Phase 1 · recruiting
- NCT04038619 — Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Ca · Phase 1 · recruiting
Other University of Freiburg trials
Trials by the same sponsor.
- NCT07517731 — Using Digital Technology for the Prevention of Aedes-Borne Diseases in Colombian Communities · NA · completed
- NCT07053631 — Investigation of a New Window Into Intracranial Pressure: Venous Occlusion Pressure of the Isolated Periorbital Vein · NA · recruiting
- NCT06301412 — Combination of Hypothermia and Thrombectomy in Acute Stroke · Phase 3 · recruiting
- NCT05414552 — ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment · completed
- NCT05811117 — Multicenter Study Using IMC to Analyze the Impact of ICANS on Microglia · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06074874 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Freiburg
- Last refreshed: 3 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06074874.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing